Therapeutic Perspectives for Microbiota Transplantation in Digestive Diseases and Neoplasia—A Literature Review DOI Creative Commons
Adrian Boicean, Dan Bratu, Ciprian Băcilă

et al.

Pathogens, Journal Year: 2023, Volume and Issue: 12(6), P. 766 - 766

Published: May 26, 2023

In a mutually beneficial connection with its host, the gut microbiota affects host's nutrition, immunity, and metabolism. An increasing number of studies have shown links between certain types disease dysbiosis or specific microorganisms. Fecal transplantation (FMT) is strongly advised for treatment recurrent resistant Clostridium difficile infection (CDI) due to outstanding clinical effectiveness against CDI. The therapeutic potential FMT other disorders, particularly inflammatory bowel diseases malignancies, currently gaining more attention. We summarized most recent preclinical evidence show promise in management cancer as well complications related after reviewing research on relationship cancer.

Language: Английский

Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial DOI Creative Commons
Maja Skov Kragsnæs,

Jennifer Rugaard Bregndahl Jensen,

Anna Christine Nilsson

et al.

RMD Open, Journal Year: 2024, Volume and Issue: 10(1), P. e003750 - e003750

Published: Jan. 1, 2024

Objectives The gut microbiota can mediate both pro and anti-inflammatory responses. In patients with psoriatic arthritis (PsA), we investigated the impact of faecal transplantation (FMT), relative to sham transplantation, on 92 inflammation-associated plasma proteins. Methods This study relates FLORA trial cohort, where 31 moderate-to-high peripheral PsA disease activity, despite at least 3 months methotrexate treatment, were included in a 26-week, double-blind, randomised, sham-controlled trial. Participants allocated receive either one gastroscopic-guided healthy donor FMT (n=15) or (n=16). Patient samples collected baseline, week 4, 12 26 while from age-matched sex-matched controls (HC) baseline. Samples analysed using proximity extension assay technology (Olink Target-96 Inflammation panel). Results Levels proteins differed significantly between HC pre-FMT (adjusted p<0.05), which 10 elevated PsA: IL-6, CCL20, CCL19, CDCP1, FGF-21, HGF, interferon-γ (IFN-γ), IL-18R1, monocyte chemotactic protein 3, IL-2. group, levels changed across all timepoints (tumour necrosis factor (TNF), IFN-γ, TWEAK, signalling lymphocytic activation molecule (SLAMF1), CD8A, CD5, Flt3L, CCL25, FGF-23, CD6, caspase-8). Significant differences sham-treated observed for TNF (p=0.002), IFN-γ (p=0.011), stem cell (p=0.024), matrix metalloproteinase-1 (p=0.038), SLAMF1 (p=0.042). had largest positive effect Axin-1 CCL25 negative CCL19 IL-6. Conclusions Patients active have distinct immunological signature compared pre-FMT. affects several these markers, including sustained elevation IFN-γ. Trial registration number NCT03058900 .

Language: Английский

Citations

9
The Complex Role of Gut Microbiota in Systemic Lupus Erythematosus and Lupus Nephritis: From Pathogenetic Factor to Therapeutic Target DOI Creative Commons
E Parodi,

M. Novi,

Paolo Bottino

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(2), P. 445 - 445

Published: Feb. 18, 2025

The role of gut microbiota (GM) and intestinal dysbiosis in triggering the onset and/or modulating severity progression lupus nephritis (LN) has been object intense research over last few years. Some alterations at phyla level, such as abundance Proteobacteria reduction Firmicutes/Bacteroidetes (F/B) ratio α-diversity have consistently reported systemic erythematosus (SLE), whereas a more specific ascribed to some species (Bacteroides thetaiotaomicron Ruminococcus gnavus) LN. Underlying mechanisms include microbial translocation through "leaky gut" subsequent molecular mimicry, immune dysregulation (alteration IFNγ levels balance between Treg Th17 subsets), epigenetic interactions. Levels bacterial metabolites, butyrate other short-chain fatty acids (SCFAs), appear play key Beyond components GM, virome mycobiome are also increasingly recognized important players modulation an response. On hand, microbiota-based therapy appears promising includes diet, prebiotics, probiotics, symbiotics, fecal transplantation (FMT). could correct critical alterations, F/B Treg/Th17 imbalance, blunt production autoantibodies renal damage. Despite current limits, GM is emerging powerful environmental factor that be harnessed interfere with leading SLE, preventing flares organ damage, including aim this review provide state-of-the-art analysis SLE LN on one while exploring possible therapeutic manipulation control disease hand.

Language: Английский

Citations

1
Gut microbiota in systemic lupus erythematosus: A fuse and a solution DOI
Yanfei Chen, Jin Lin, Lanlan Xiao

et al.

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 132, P. 102867 - 102867

Published: Aug. 3, 2022

Language: Английский

Citations

37
Gut Barrier Damage and Gut Translocation of Pathogen Molecules in Lupus, an Impact of Innate Immunity (Macrophages and Neutrophils) in Autoimmune Disease DOI Open Access
Awirut Charoensappakit,

Kritsanawan Sae‐khow,

Asada Leelahavanichkul

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(15), P. 8223 - 8223

Published: July 26, 2022

The gut barrier is a single cell layer that separates micro-organisms from the host, and permeability defects result in translocation of microbial molecules into blood. Despite silent clinical manifestation, can induce systemic inflammation might be an endogenous exacerbating factor lupus erythematosus. In contrast, circulatory immune-complex deposition effect medications on gut, organ with extremely large surface area, patients active cause molecules, which worsens severity. Likewise, imbalance microbiota may initiate and/or interfere integrity results exacerbation. Moreover, immune hyper-responsiveness innate cells (macrophages neutrophils) demonstrated model loss inhibitory Fc gamma receptor IIb (FcgRIIb), induces prominent responses through cross-link between activating-FcgRs receptors. death, especially apoptosis neutrophil extracellular traps (NETosis), possibly exacerbates lupus, partly enhanced exposure self-antigens. Leaky monitoring treatments (such as probiotics) beneficial lupus. Here, we discuss current information leaky

Language: Английский

Citations

35
Challenges and costs of donor screening for fecal microbiota transplantations DOI Creative Commons
Mèlanie V. Bénard, Clara M.A. de Bruijn, Aline C. Fenneman

et al.

PLoS ONE, Journal Year: 2022, Volume and Issue: 17(10), P. e0276323 - e0276323

Published: Oct. 20, 2022

Background The increasing interest to perform and investigate the efficacy of fecal microbiota transplantation (FMT) has generated an urge for feasible donor screening. We report our experience with stool recruitment, screening, follow-up, associated costs in context clinical FMT trials. Methods Potential donors, aged between 18−65 years, underwent a stepwise screening process starting extensive questionnaire followed by feces blood investigations. When eligible, donors were rescreened MDROs SARS-CoV-2 every 60-days, full rescreening 4−6 months. find retain calculated. Results From January 2018 August 2021, 393 potential prescreening, which 202 (51.4%) did not proceed primarily due loss medication use, or logistic reasons (e.g. COVID-19 measures). 191 filled questionnaire, 43 (22.5%) excluded. remaining 148 candidates parasitology screening: 91 (61.5%) excluded, mostly Dientamoeba fragilis and/or high amounts Blastocystis spp. After additional investigations 18/57 (31.6%) excluded (mainly presence Helicobacter Pylori ESBL-producing organisms). One failed serum testing. Overall, 38 out (10%) enrolled. median participation time active was 13 To recruit €64.112 spent. Conclusion Recruitment is challenging. In Dutch cohort, eligibility often caused protozoa spp.. exclusion that carry these protozoa, especially spp., questionable deserves reconsideration. High-quality substantial costs.

Language: Английский

Citations

29
The Evolving Landscape of Fecal Microbial Transplantation DOI Open Access
Tihong Shao,

Ronald Hsu,

Camelia Hacein-Bey

et al.

Clinical Reviews in Allergy & Immunology, Journal Year: 2023, Volume and Issue: 65(2), P. 101 - 120

Published: Feb. 9, 2023

Language: Английский

Citations

22
Fecal microbiota transplantation for the management of autoimmune diseases: Potential mechanisms and challenges DOI
Xiaomin Liu, Mei Liu, Ming Zhao

et al.

Journal of Autoimmunity, Journal Year: 2023, Volume and Issue: 141, P. 103109 - 103109

Published: Sept. 10, 2023

Language: Английский

Citations

21
The role of gut microbiota and metabolites in cancer chemotherapy DOI Creative Commons
Shiyu Li, Shuangli Zhu, Jun Yu

et al.

Journal of Advanced Research, Journal Year: 2023, Volume and Issue: 64, P. 223 - 235

Published: Nov. 26, 2023

The microbiota inhabits the epithelial surfaces of hosts, which influences physiological functions from helping digest food and acquiring nutrition to regulate metabolism shaping host immunity. With deep insight into microbiota, an increasing amount research reveals that it is also involved in initiation progression cancer. Intriguingly, gut can mediate biotransformation drugs, thereby altering their bioavailability, bioactivity, or toxicity. Review review aims elaborate on role microbial metabolites efficacy adverse effects chemotherapeutics. Furthermore, we discuss clinical potential various ways harness for cancer chemotherapy. Key Scientific Concepts Recent evidence shows modulates toxicity chemotherapy agents, leading diverse responses Thereinto, targeting improve diminish chemotherapeutic drugs may be a promising strategy tumor treatment.

Language: Английский

Citations

19
A single-cell map of peripheral alterations after FMT treatment in patients with systemic lupus erythematosus DOI
Meiling Zheng, Wenhui Zhou, Cancan Huang

et al.

Journal of Autoimmunity, Journal Year: 2023, Volume and Issue: 135, P. 102989 - 102989

Published: Jan. 5, 2023

Language: Английский

Citations

18
Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives DOI Creative Commons
Eya Toumi,

Soraya Mezouar,

Anne Plauzolles

et al.

Lupus Science & Medicine, Journal Year: 2023, Volume and Issue: 10(1), P. e000776 - e000776

Published: Feb. 1, 2023

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE characterised breaking self-immune tolerance autoantibody production that triggers inflammation damage of multiple organs. Given the highly heterogeneous nature SLE, treatments currently used are still not satisfactory with considerable side effects, development new therapies major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge pathogenesis an invaluable tool testing novel therapeutic targets. Here, we discuss role most their contribution improvement. Considering complexity developing targeted adjuvant also increasingly proposed. Indeed, murine human studies have recently revealed gut microbiota potential target holds great promises successful therapies. However, mechanisms dysbiosis in remain unclear date. review, propose inventory existing investigating relationship establish microbiome signature may serve as biomarker its severity well therapy target. This approach open possibilities early diagnosis, prevention perspectives based on microbiome.

Language: Английский

Citations

18